In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the benefits of combining parsaclisib with ruxolitinib as a treatment approach for patients with myelofibrosis (MF) who have a suboptimal response to JAK inhibitor monotherapy. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.